ARGENX SE - ADR

ARGX · NASDAQ

Updated at 2026-11-16 23:31:40

$950.95-0.94%
Today's High
$981.42
Today’s Low
$948.21
ARGENX SE - ADR (ARGX) Stock Price & Market Data
Search empty state illustration
...

Candlestick trends are for reference. Refer to the trading page for actual data.

Key Statistics

Previous Open
$975.62
Previous Close
$960.04
Volume
225.89K
Market Cap
$60.37B
P/E Ratio
32.72X
EPS
$28.95

Previous Day Range

$959.27$976.85

52-Week Range

$568.40$925.00

Company Overview

Sector
HEALTHCARE
Industry
Biotechnology
Sub-industry
BIOTECHNOLOGY
Headquarters
LAARDERHOOGTWEG 25, AMSTERDAM, NETHERLANDS, 1101 EB
Country
NL
Listing Date
2014-07-10
Fiscal Year End
December
Shares Outstanding
62.89M
CIK
0001697862

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Financial Metrics

Revenue

2026-09-30

$1.72B

2026-06-30

$2.81B

2026-03-31

$1.29B

2025-12-31

$3.2B

Operating Expenses

2026-09-30

$1.07B

2026-06-30

$1.68B

2026-03-31

$904M

2025-12-31

$2.01B

Net Income

2026-09-30

$506M

2026-06-30

$838.82M

2026-03-31

$366M

2025-12-31

$1.04B

Net Profit Margin

2026-09-30

29.4%

2026-06-30

29.79%

2026-03-31

28.19%

2025-12-31

32.65%

Earnings Per Share

2026-09-30

$7.80

2026-06-30

$7.32

2026-03-31

$5.52

2025-12-31

$8.02

Earnings Before Interest, Taxes, Depreciation, and Amortization

2026-09-30

$539M

2026-06-30

$863.84M

2026-03-31

$427M

2025-12-31

$1B

Effective Tax Rate

2026-09-30

5.94%

2026-06-30

12.42%

2026-03-31

--

2025-12-31

-5.54%

FAQs

Risk Warning

Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.